The Venture Codex

Participated · Series B · Apr 2026

Nervonik is developing a next-generation peripheral nerve stimulation platform that combines electrical stimulation with advanced sensing to enable more precise, personalized neuromodulation therapies. Its implantable leads have demonstrated the ability to record evoked compound action potentials (ECAPs) and other physiological biomarkers. The company is advancing clinical programs and preparing for commercialization of its PNS system. Recent financing will fund further development of its proprietary sensing capabilities and support commercialization activities. Nervonik is headquartered in Los Angeles, California.

Led · Convertible Note · Mar 2026

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.

Led · Series C · Jan 2026

Nuclera is a biotechnology company building eProtein Discovery, a desktop platform that integrates cell-free protein expression, digital microfluidics, and high-throughput screening to give researchers rapid access to purified proteins. The system reduces the time, cost, and uncertainty of protein production, allowing scientists to identify and validate candidates earlier in the drug-discovery process. With its latest focus on AI-enabled protein engineering, Nuclera is adding antibody-specific capabilities so users can perform end-to-end expression, purification, and binding validation of full-format antibodies on the same device. These new features are designed to generate large, standardized data sets suitable for training advanced machine-learning models in biologics R&D. Management positions the platform as a foundational tool for the fast-growing biologics segment, aiming to shorten therapeutic discovery timelines. The firm’s ongoing development is backed by considerable venture financing, now totaling $87 million in Series C capital.

Led · Series B · Dec 2025

Biobeat Technologies, Ltd. has created a disposable, patch-based ambulatory blood pressure monitoring (ABPM) system that collects continuous, 24-hour blood-pressure data without the discomfort of traditional cuff inflation cycles. The sensor allows patients to conduct normal daily activities and sleep undisturbed, after which a high-quality report is automatically uploaded to the institution’s electronic medical records. With operations in Tel Aviv and Boca Raton, the company is focused on making ABPM a standard of care for more than 100 million hypertensive patients in the United States. Biobeat’s solution is already FDA-cleared and positioned to replace cumbersome cuff-based devices that suffer from poor patient compliance. The firm plans to use its newly raised capital to build a field sales team and accelerate U.S. commercialization. Financially, Biobeat just secured a $50 million Series B round, adding to its resources for market expansion and product roll-out.

Participated · Series C · Sep 2025

Galvanize Therapeutics develops and commercializes a pulsed electric field (PEF) platform that uses non-thermal, short-duration, highly focused electrical pulses to modulate biologic processes. Its lead programs include the Aliya® PEF system for solid tumors and RheOx® therapy for chronic bronchitis. The company is commercial-stage and intends to expand its commercial footprint in the United States. Galvanize plans to advance clinical and development activities across its oncology and chronic lung disease programs. Management says it will continue to innovate its novel, non-pharmacologic PEF platform to address unmet needs in patients underserved by pharmaceutical approaches. The company is based in Redwood City, California. Galvanize Therapeutics commercializes the Aliya Pulsed Electric Field (PEF) energy platform, a non-thermal high-voltage, high-frequency electrical system designed to alter cellular physiology for ablation and drug delivery. The company has multiple product lines: RheOx for chronic bronchitis (CE Mark, launched in select European hospitals), CENTAURI for cardiac arrhythmias (CE Mark, launching in Europe), and the Aliya system for soft tissue ablation (recent U.S. FDA 510(k) clearance, launching at select U.S. hospitals). Galvanize is also studying Aliya in immuno-oncology (preclinical and early clinical signals of immune activation) and developing a local drug-delivery system. The company was formed by ATP in 2022 through the merger of Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics and is headquartered in San Carlos, Calif. Management says it is investing to prove safety and demonstrate enhanced outcomes in initial clinical targets while exploring additional platform applications.